Iquum Gets FDA OK for Flu A/B Test; Eyes More Assays for Its Automated MDx System | GenomeWeb

By Ben Butkus

Clinical diagnostic test maker Iquum this week received US Food and Drug Administration clearance for its Liat Influenza A/B assay and fully automated and integrated Liat Analyzer.

Iguum said the real-time PCR-based test — its first 510(k) win — is designed to enable clinical labs to detect and differentiate influenza A and B in about 20 minutes, or about as fast as currently used immunoassays, but with the increased sensitivity afforded by nucleic acid testing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.